晶泰控股子公司携手礼来达成战略合作 共推双特异性抗体开发

财中社
Nov 05

  11月5日,晶泰控股(02228)发布公告,旗下全资子公司上海艾乐晞生物科技有限公司与礼来公司达成基于平台的战略合作,以加快用于治疗多种疾病的双特异性抗体的发现及开发。

  根据合作条款,礼来将可提名靶点进行双特异性抗体设计,并可获得Ailux专利平台的使用许可。合作包括预付款及近期里程碑付款,总额为数千万美元,潜在总值可达3.45亿元。

  Ailux作为晶泰的专属生物制药创新平台,致力于通过AI驱动的解决方案开发先进的生物疗法。该平台结合专有计算模型与尖端湿实验能力,旨在攻克传统不可成药靶点,设计具有创新药潜力的生物药分子。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10